RMTI
RMTI clinical trials: ROCKWELL MEDICAL, INC.
Every trial on ClinicalTrials.gov where ROCKWELL MEDICAL, INC. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 20
- Trials linked
- 19
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
RMTI on the catalyst calendar · RMTI registry changes
- Primary completion Jun 19, 2021ActualPhase 4NCT04689932Triferic AVNU Infusion Via Freedom Pump During HemodialysisRockwell Medical Technologies, Inc. · End Stage Renal DiseaseCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 30, 2022Sponsor estimatePhase 2NCT05110768Treatment of (IDA) by (FPC) Delivered Via Infusion Pump in Patients Receiving Home Infusion TherapyRockwell Medical Technologies, Inc. · Iron Deficiency AnemiaUnknown statusRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2, 2021ActualPhase 1/Phase 2NCT04409132Study to Investigate the Pharmacokinetic Comparability of Dosing Triferic AVNU IV by Continuous Infusion and IV Bolus.Rockwell Medical Technologies, Inc. · End Stage Renal DiseaseCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 31, 2023Sponsor estimatePhase 3NCT04239391Hemoglobin Maintenance in Pediatric ESRD (End-stage Renal Disease) Patients by Ferric Pyrophosphate Citrate (FPC)Rockwell Medical Technologies, Inc. · End Stage Renal DiseaseUnknown statusRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 16, 2020ActualPhase 1/Phase 2NCT04042324A Study to Investigate the Effect of Triferic Plus Heparin Infusion Compared to Heparin Alone on Coagulation Parameters in Hemodialysis...Rockwell Medical Technologies, Inc. · End Stage Renal DiseaseCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2009ActualPhase 2NCT00548249Dose Ranging Study of Dialysate Containing Soluble Iron to Treat Subjects With End Stage Renal Disease (ESRD) Receiving Chronic HemodialysisRockwell Medical Technologies, Inc. · End-Stage Renal Disease (ESRD)CompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 28, 2017ActualPhase 1/Phase 2NCT03303144Equivalence of Triferic® (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD PatientsRockwell Medical Technologies, Inc. · End Stage Renal DiseaseCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 15, 2018ActualPhase 2NCT02905981Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) ProtocolRockwell Medical Technologies, Inc. · Iron-Refractory Iron-Deficiency AnemiaTerminatedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2017ActualPhase 1NCT02909153Study of Intraperitoneal Triferic in Patients on Chronic Peritoneal DialysisRockwell Medical Technologies, Inc. · Peritoneal Dialysis (PD)CompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 2015ActualPhase 1NCT02636049Pharmacokinetics of Triferic (Ferric Pyrophosphate Citrate) Administered Intravenously to Healthy Adult VolunteersRockwell Medical Technologies, Inc. · End Stage Renal DiseaseCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2016ActualPhase 1/Phase 2NCT02595437Triferic Pediatric Pharmacokinetic ProtocolRockwell Medical Technologies, Inc. · End Stage Renal DiseaseCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2016ActualPhase 1NCT02767128Pharmacokinetics and Absolute Bioavailability of Fer-In-Sol and Triferic Administered Orally With Shohl's Solution in Healthy VolunteersRockwell Medical Technologies, Inc. · Iron-refractory, Iron-deficiency Anemia (IRIDA)CompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 2016ActualPhase 1NCT02739100Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and...Rockwell Medical Technologies, Inc. · End Stage Renal DiseaseCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2013ActualPhase 2NCT01286012Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis PatientsRockwell Medical Technologies, Inc. · End Stage Renal DiseaseCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2014ActualPhase 3NCT01322347Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)Rockwell Medical Technologies, Inc. · Renal Failure Chronic Requiring HemodialysisCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2013ActualPhase 3NCT01320202Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis PatientsRockwell Medical Technologies, Inc. · Renal Failure Chronic Requiring HemodialysisCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 2014ActualPhase 3NCT01503021Safety Study of Soluble Ferric Pyrophosphate (SFP) in Dialysate in CKD Patients Receiving Chronic HemodialysisRockwell Medical Technologies, Inc. · End Stage Renal DiseaseCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2013ActualPhase 1/Phase 2NCT01894906Quantitative Mass Transfer of SFP-iron From Dialysate to Blood in CKD-HD PatientsRockwell Medical Technologies, Inc. · Kidney FailureCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2013ActualPhase 1NCT01920854A Single Ascending Dose Study of Soluble Ferric Pyrophosphate Administered Intravenously in Healthy Volunteers.Rockwell Medical Technologies, Inc. · Kidney Failure, Chronic Therapy; HemodialysisCompletedRMTILead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2010ActualNo phase registeredNCT00604565Delivery of Soluble Ferric Pyrophosphate (SFP) Via the Dialysate to Maintain Iron Balance in Hemodialysis PatientsCharles Drew University of Medicine and Science · End Stage Renal Disease (ESRD)TerminatedRMTICollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 20 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner